ExpreS2ion Biotech Holding AB (EXPRS2) — Cash Flow-to-Debt Ratio
ExpreS2ion Biotech Holding AB (EXPRS2) has a Cash Flow-to-Debt Ratio of -1.06x as of March 2026, meaning its operating cash flow of Skr-25.49 Million could theoretically repay -1% of its total liabilities (Skr23.98 Million) in one year. Check how aggressively does ExpreS2ion Biotech Holding AB reinvest cash to assess the company's total reinvestment commitment from operating cash flow.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
ExpreS2ion Biotech Holding AB Cash Flow-to-Debt Ratio (2016–2025)
Historical debt coverage capacity for ExpreS2ion Biotech Holding AB across 10 annual periods. Also explore how large is ExpreS2ion Biotech Holding AB's balance sheet for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for ExpreS2ion Biotech Holding AB (2016–2025)
Year-by-year debt coverage analysis for ExpreS2ion Biotech Holding AB. For market capitalisation and broader financial context, see ExpreS2ion Biotech Holding AB market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (SEK) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -1.39x | Skr-40.90 Million | Skr29.42 Million | ▼ -64.4% |
| 2024 | -0.85x | Skr-33.93 Million | Skr40.11 Million | ▲ +88.8% |
| 2023 | -7.57x | Skr-100.89 Million | Skr13.33 Million | ▼ -158.6% |
| 2022 | -2.93x | Skr-99.61 Million | Skr34.04 Million | ▲ +25.6% |
| 2021 | -3.93x | Skr-45.65 Million | Skr11.61 Million | ▼ -425.9% |
| 2020 | -0.75x | Skr-18.18 Million | Skr24.31 Million | ▼ -16.6% |
| 2019 | -0.64x | Skr-12.69 Million | Skr19.79 Million | ▲ +37.0% |
| 2018 | -1.02x | Skr-12.88 Million | Skr12.65 Million | ▼ -24.1% |
| 2017 | -0.82x | Skr-8.61 Million | Skr10.50 Million | ▼ -37.1% |
| 2016 | -0.60x | Skr-7.02 Million | Skr11.73 Million | — |